Pharma market growth: India’s pharmaceutical market began FY27 on a firm note. Pharmarack data show that the Indian Pharmaceutical Market expanded 10.3% year-on-year in April to Rs 21,745 crore, from Rs 19,711 crore in April 2025. In a year marked by global uncertainty, domestic demand remains the industry’s strongest cushion.
The expansion was broad-based, but the centre of gravity has shifted. Chronic therapies, especially anti-diabetes, cardiac and respiratory segments, drove the April numbers. Anti-diabetes therapies grew 16.2% in value, aided by rising prevalence of lifestyle diseases and newer combinations such as empagliflozin-based drugs. Cardiac therapies grew 14.3%. Respiratory therapies also recorded a sharp increase.
This is no longer a market led mainly by seasonal infections and acute care. India’s pharma market is moving steadily towards long-term disease management.
READ | Pharmaceutical industry risks rise amid US tariff threat
Chronic disease burden drives demand
The shift reflects India’s changing disease profile. Diabetes, hypertension and cardiovascular disease now account for a large share of the disease burden. ICMR estimates suggest that nearly one in four Indians faces the lifetime risk of developing diabetes. That creates sustained demand for medicines and recurring revenues for drug companies.
Acute therapies remain important, but they depend more on infections, weather patterns and seasonal spikes. Chronic therapies are more predictable. They bind patients to long treatment cycles and give companies greater visibility on revenue.
Indian firms have also benefited from the branded generics model. Unlike developed markets, where generics are largely commoditised, Indian companies operate in a market where brands, doctors’ prescriptions and distribution strength still matter. This gives firms some pricing flexibility, even within tightly contested market.
Combination drugs, especially in diabetes and obesity management, have helped companies defend margins while responding to new patient needs. This is innovation within the generics space, not breakthrough drug discovery. But in the Indian market, it remains commercially powerful.
Indian pharma investment in US signals global ambition
Indian pharmaceutical companies are also deepening their presence in the United States, the world’s largest drug market. At the 2026 SelectUSA Investment Summit, Indian industry announced plans to invest $20.5 billion in the US economy. Pharmaceutical companies accounted for nearly $19.1 billion of these commitments.
READ | India-China pharma trade opens up a $6 bn opportunity
This marks a change in posture. Indian companies are not merely exporters of low-cost generics. They are becoming investors, manufacturers and strategic partners in end markets.
The proposed investments include major firms such as Sun Pharma, Cipla, Lupin, Zydus and Dr Reddy’s. Sun Pharma accounts for $11.75 billion through its planned acquisition of New Jersey-based Organon & Co. The scale of these commitments shows how Indian firms are moving closer to customers, diversifying production locations and reducing exposure to geopolitical and trade shocks.
The logic is clear. The US remains central to Indian pharma’s global strategy, but it is also a market under pressure. Being closer to the market can help companies manage regulation, distribution and political risk better than a pure export model.
Pricing pressure squeezes Indian pharma margins
The domestic market is not free of stress. The National Pharmaceutical Pricing Authority continues to expand oversight of essential medicines and cap prices in critical therapeutic categories. This improves affordability, but it limits margins.
The global picture is no easier. Indian companies derive a significant share of revenue from exports, particularly to the United States. In the US generics market, price erosion remains persistent. Consolidation among distributors, pharmacy benefit managers and retail chains has increased buyer power. Indian firms face tougher bargaining conditions than they did a decade ago.
Regulatory scrutiny has also intensified. The US Food and Drug Administration remains strict on inspections, data integrity and manufacturing standards. Compliance costs are rising. Companies that fail to maintain quality systems risk warning letters, import alerts and supply disruptions.
Quality is now a market-access issue, not a back-office compliance matter. CDSCO tested 1,16,323 drug samples between April 2024 and March 2025; 2,652 were found not of standard quality and 245 were adulterated. Recent US FDA actions against Indian facilities have also cited data-integrity, record-keeping and manufacturing-control lapses. For an industry that seeks to supply both India’s chronic-care market and heavily regulated export markets, credibility will rest as much on inspection outcomes as on cost competitiveness.
The pressure is not only about price. It is also about capability. Global markets are shifting towards biosimilars and complex generics. These are higher-value segments, but they demand deeper research, stronger regulatory capacity and sustained capital expenditure. Large firms have begun the transition. Smaller firms will find it harder.
READ | Pharma innovation: Why India must move on from generics
API dependence remains the weak link
The global pharma ecosystem is being reshaped by tariffs, supply-chain realignment and geopolitical tension. India has gained from the search for alternatives to concentrated supply chains. But it still depends heavily on China for active pharmaceutical ingredients.
That dependence remains the sector’s most visible vulnerability. A disruption in API supply can raise costs, delay production and weaken India’s export reliability. The lesson from the pandemic was clear: manufacturing strength is incomplete without input security.
The government has tried to correct this through Production Linked Incentive schemes for bulk drugs and API manufacturing. These incentives have helped revive policy attention, but financial support alone cannot build a resilient supply chain. India needs infrastructure, environmental clearances, technology capability and reliable utilities. Without these, domestic API production will remain a partial answer.
For now, Indian pharma operates with strong downstream capacity and continued upstream dependence.
India pharma growth needs quality, not just volume
The sector’s fundamentals remain strong. India has a large domestic market, a deep manufacturing base and a global reputation as the pharmacy of the world. It supplies more than 20% of global generic medicines and plays a crucial role in vaccine production.
But the next phase will be more demanding. Volume growth alone will not secure leadership. The quality of growth will matter more. Companies will need to move into complex generics, biosimilars and higher-value therapies while maintaining affordability in the domestic market.
Policy support must also move beyond incentives. India needs faster approvals, stronger quality systems, predictable pricing policy and credible regulatory oversight. A sector that seeks global leadership cannot treat compliance as a cost. It must treat it as market access.
April’s numbers show resilience. They also show a transition. India’s pharma market is becoming more chronic-care driven, more globally invested and more exposed to quality and supply-chain risks. The opportunity is large. So is the burden of execution.